Biosurgery startup LifeBond raised $8 million from Pitango and Omrix founder Taub

Biosurgery products development startup LifeBond has raised $8 million in a second financing round led by Pitango Venture Capital and Robert Taub, founder and former CEO of Omrix Biopharmaceuticals, which recently acquired by Johnson & Johnson for $438 million. Existing investors: GlenRock Israel, Leon Recanati’s investment company, and Zitelman Group, also participating in this round.

LifeBond is developing surgical sealants and hemostats intended for preventing leakage and bleeding. Proceeds from the round will be used for the completion of the pre-clinical and clinical phases of the Company’s initial product: LifeSeal SLR, a sealant indicated for reinforcement of gastro-intestinal anastomoses. The company anticipates that LifeSeal SLR will reach the market in 2011, pending regulatory approval in the U.S., Europe and Israel.

LifeBond was founded in 2007 by Ishay Attar, the current LifeBond CEO, Orahn Preiss-Bloom, LifeBond VP Operations, and Nir Mashkif. The company received seed funding from the Trendlines Israel Fund, followed by a $1.5 million round A financing round led by GlenRock Israel. The Company’s headquarters and research center are located in Caesarea Industrial Park.

Sponsored Links – Intermittent Pneumatic Compression | Psoriasis Treatment | Test Management Tool for Mantis Bugs Tracker